Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Common genetic variation in TP53 and risk of human papillomavirus persistence and progression to CIN3/cancer revisited.

Koshiol J, Hildesheim A, Gonzalez P, Bratti MC, Porras C, Schiffman M, Herrero R, Rodriguez AC, Wacholder S, Yeager M, Chanock SJ, Burk RD, Wang SS.

Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1631-7. doi: 10.1158/1055-9965.EPI-08-0830.

2.

Common variants in immune and DNA repair genes and risk for human papillomavirus persistence and progression to cervical cancer.

Wang SS, Bratti MC, Rodríguez AC, Herrero R, Burk RD, Porras C, González P, Sherman ME, Wacholder S, Lan ZE, Schiffman M, Chanock SJ, Hildesheim A.

J Infect Dis. 2009 Jan 1;199(1):20-30. doi: 10.1086/595563.

3.

Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial.

Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, Schiller JT, Gonzalez P, Dubin G, Porras C, Jimenez SE, Lowy DR; Costa Rican HPV Vaccine Trial Group.

JAMA. 2007 Aug 15;298(7):743-53.

PMID:
17699008
4.

Comparison of the SPF10-LiPA system to the Hybrid Capture 2 Assay for detection of carcinogenic human papillomavirus genotypes among 5,683 young women in Guanacaste, Costa Rica.

Safaeian M, Herrero R, Hildesheim A, Quint W, Freer E, Van Doorn LJ, Porras C, Silva S, González P, Bratti MC, Rodriguez AC, Castle P; Costa Rican Vaccine Trial Group.

J Clin Microbiol. 2007 May;45(5):1447-54. Epub 2007 Mar 7.

5.

Right-sided ectocervical lesions may be associated with false-negative cytology among women with histologic cervical intraepithelial neoplasia 2 or 3.

Jeronimo J, Castle PE, Herrero R, Sherman ME, Bratti MC, Hildesheim A, Alfaro M, Morales J, Hutchinson ML, Burk RD, Lorincz A, Wacholder S, Rodríguez AC, Schiffman M.

J Low Genit Tract Dis. 2003 Jul;7(3):175-83.

PMID:
17051065
6.

Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality.

Kovacic MB, Castle PE, Herrero R, Schiffman M, Sherman ME, Wacholder S, Rodriguez AC, Hutchinson ML, Bratti MC, Hildesheim A, Morales J, Alfaro M, Burk RD.

Cancer Res. 2006 Oct 15;66(20):10112-9.

7.

Age-related changes of the cervix influence human papillomavirus type distribution.

Castle PE, Jeronimo J, Schiffman M, Herrero R, Rodríguez AC, Bratti MC, Hildesheim A, Wacholder S, Long LR, Neve L, Pfeiffer R, Burk RD.

Cancer Res. 2006 Jan 15;66(2):1218-24.

8.

Human leukocyte antigen class I and II haplotypes and risk of cervical cancer.

Carreon JD, Martin MP, Hildesheim A, Gao X, Schiffman M, Herrero R, Bratti MC, Sherman ME, Zaino RJ, Carrington M, Wang SS.

Tissue Antigens. 2005 Oct;66(4):321-4.

PMID:
16185329
9.

The carcinogenicity of human papillomavirus types reflects viral evolution.

Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, Bratti MC, Sherman ME, Morales J, Guillen D, Alfaro M, Hutchinson M, Wright TC, Solomon D, Chen Z, Schussler J, Castle PE, Burk RD.

Virology. 2005 Jun 20;337(1):76-84.

10.

A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica.

Castle PE, Schiffman M, Herrero R, Hildesheim A, Rodriguez AC, Bratti MC, Sherman ME, Wacholder S, Tarone R, Burk RD.

J Infect Dis. 2005 Jun 1;191(11):1808-16. Epub 2005 May 2.

PMID:
15871112
11.

Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica.

Herrero R, Castle PE, Schiffman M, Bratti MC, Hildesheim A, Morales J, Alfaro M, Sherman ME, Wacholder S, Chen S, Rodriguez AC, Burk RD.

J Infect Dis. 2005 Jun 1;191(11):1796-807. Epub 2005 May 2.

PMID:
15871111
12.

PCR testing of pooled longitudinally collected cervical specimens of women to increase the efficiency of studying human papillomavirus infection.

Castle PE, Schiffman M, Herrero R, Hildesheim A, Rodriguez AC, Bratti MC, Wacholder S, Kendal H, Breheny AM, Prior A, Pfeiffer R, Burk RD.

Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):256-60.

13.

A study of the impact of adding HPV types to cervical cancer screening and triage tests.

Schiffman M, Khan MJ, Solomon D, Herrero R, Wacholder S, Hildesheim A, Rodriguez AC, Bratti MC, Wheeler CM, Burk RD; PEG Group; ALTS Group.

J Natl Cancer Inst. 2005 Jan 19;97(2):147-50.

PMID:
15657345
14.

Validation of p16INK4a as a marker of oncogenic human papillomavirus infection in cervical biopsies from a population-based cohort in Costa Rica.

Wang SS, Trunk M, Schiffman M, Herrero R, Sherman ME, Burk RD, Hildesheim A, Bratti MC, Wright T, Rodriguez AC, Chen S, Reichert A, von Knebel Doeberitz C, Ridder R, von Knebel Doeberitz M.

Cancer Epidemiol Biomarkers Prev. 2004 Aug;13(8):1355-60.

15.

Determinants of human papillomavirus 16 serological conversion and persistence in a population-based cohort of 10 000 women in Costa Rica.

Wang SS, Schiffman M, Herrero R, Carreon J, Hildesheim A, Rodriguez AC, Bratti MC, Sherman ME, Morales J, Guillen D, Alfaro M, Clayman B, Burk RD, Viscidi RP.

Br J Cancer. 2004 Oct 4;91(7):1269-74.

16.

A population-based study of vaginal human papillomavirus infection in hysterectomized women.

Castle PE, Schiffman M, Bratti MC, Hildesheim A, Herrero R, Hutchinson ML, Rodriguez AC, Wacholder S, Sherman ME, Kendall H, Viscidi RP, Jeronimo J, Schussler JE, Burk RD.

J Infect Dis. 2004 Aug 1;190(3):458-67. Epub 2004 Jul 2.

PMID:
15243917
17.

Description of a seven-year prospective study of human papillomavirus infection and cervical neoplasia among 10000 women in Guanacaste, Costa Rica,.

Bratti MC, Rodríguez AC, Schiffman M, Hildesheim A, Morales J, Alfaro M, Guillén D, Hutchinson M, Sherman ME, Eklund C, Schussler J, Buckland J, Morera LA, Cárdenas F, Barrantes M, Pérez E, Cox TJ, Burk RD, Herrero R.

Rev Panam Salud Publica. 2004 Feb;15(2):75-89.

PMID:
15030652
18.

Comparison of ophthalmic sponges for measurements of immune markers from cervical secretions.

Castle PE, Rodriguez AC, Bowman FP, Herrero R, Schiffman M, Bratti MC, Morera LA, Schust D, Crowley-Nowick P, Hildesheim A.

Clin Diagn Lab Immunol. 2004 Mar;11(2):399-405.

19.

Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica.

Viscidi RP, Schiffman M, Hildesheim A, Herrero R, Castle PE, Bratti MC, Rodriguez AC, Sherman ME, Wang S, Clayman B, Burk RD.

Cancer Epidemiol Biomarkers Prev. 2004 Feb;13(2):324-7.

20.

Immune profiling of plasma and cervical secretions using recycling immunoaffinity chromatography.

Castle PE, Phillips TM, Hildesheim A, Herrero R, Bratti MC, Rodríguez AC, Morera LA, Pfeiffer R, Hutchinson ML, Pinto LA, Schiffman M.

Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1449-56.

21.

Stability of archived liquid-based cytologic specimens.

Castle PE, Hildesheim A, Schiffman M, Gaydos CA, Cullen A, Herrero R, Bratti MC, Freer E.

Cancer. 2003 Oct 25;99(5):320-2. No abstract available.

22.

Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica.

Wang SS, Schiffman M, Shields TS, Herrero R, Hildesheim A, Bratti MC, Sherman ME, Rodriguez AC, Castle PE, Morales J, Alfaro M, Wright T, Chen S, Clayman B, Burk RD, Viscidi RP.

Br J Cancer. 2003 Oct 6;89(7):1248-54.

23.

A comparison of single and combined visual, cytologic, and virologic tests as screening strategies in a region at high risk of cervical cancer.

Ferreccio C, Bratti MC, Sherman ME, Herrero R, Wacholder S, Hildesheim A, Burk RD, Hutchinson M, Alfaro M, Greenberg MD, Morales J, Rodriguez AC, Schussler J, Eklund C, Marshall G, Schiffman M.

Cancer Epidemiol Biomarkers Prev. 2003 Sep;12(9):815-23.

24.

A comparison between real-time polymerase chain reaction and hybrid capture 2 for human papillomavirus DNA quantitation.

Gravitt PE, Burk RD, Lorincz A, Herrero R, Hildesheim A, Sherman ME, Bratti MC, Rodriguez AC, Helzlsouer KJ, Schiffman M.

Cancer Epidemiol Biomarkers Prev. 2003 Jun;12(6):477-84.

25.

Correlates of IL-10 and IL-12 concentrations in cervical secretions.

Gravitt PE, Hildesheim A, Herrero R, Schiffman M, Sherman ME, Bratti MC, Rodriguez AC, Morera LA, Cardenas F, Bowman FP, Shah KV, Crowley-Nowick PA.

J Clin Immunol. 2003 May;23(3):175-83.

PMID:
12797539
26.

Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types.

Castle PE, Schiffman M, Burk RD, Wacholder S, Hildesheim A, Herrero R, Bratti MC, Sherman ME, Lorincz A.

Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1394-9.

27.

Comparisons of HPV DNA detection by MY09/11 PCR methods.

Castle PE, Schiffman M, Gravitt PE, Kendall H, Fishman S, Dong H, Hildesheim A, Herrero R, Bratti MC, Sherman ME, Lorincz A, Schussler JE, Burk RD.

J Med Virol. 2002 Nov;68(3):417-23.

PMID:
12226831
28.

Comprehensive analysis of human leukocyte antigen class I alleles and cervical neoplasia in 3 epidemiologic studies.

Wang SS, Hildesheim A, Gao X, Schiffman M, Herrero R, Bratti MC, Sherman ME, Barnes WA, Greenberg MD, McGowan L, Mortel R, Schwartz PE, Zaino RJ, Glass AG, Burk RD, Karacki P, Carrington M.

J Infect Dis. 2002 Sep 1;186(5):598-605. Epub 2002 Jul 29.

PMID:
12195346
29.

Can cervicography be improved? An evaluation with arbitrated cervicography interpretations.

Schneider DL, Burke L, Wright TC, Spitzer M, Chatterjee N, Wacholder S, Herrero R, Bratti MC, Greenberg MD, Hildesheim A, Sherman ME, Morales J, Hutchinson ML, Alfaro M, Lörincz A, Schiffman M.

Am J Obstet Gynecol. 2002 Jul;187(1):15-23.

PMID:
12114883
30.

Human leukocyte antigen class I alleles and cervical neoplasia: no heterozygote advantage.

Wang SS, Hildesheim A, Gao X, Schiffman M, Herrero R, Bratti MC, Sherman ME, Barnes WA, Greenberg MD, McGowan L, Mortel R, Schwartz PE, Zaino RJ, Glass AG, Burk RD, Karacki P, Carrington M.

Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):419-20. No abstract available.

31.

Human leukocyte antigen class I and II alleles and risk of cervical neoplasia: results from a population-based study in Costa Rica.

Wang SS, Wheeler CM, Hildesheim A, Schiffman M, Herrero R, Bratti MC, Sherman ME, Alfaro M, Hutchinson ML, Morales J, Lorincz A, Burk RD, Carrington M, Erlich HA, Apple RJ.

J Infect Dis. 2001 Nov 15;184(10):1310-4. Epub 2001 Oct 29.

PMID:
11679920
32.

An association of cervical inflammation with high-grade cervical neoplasia in women infected with oncogenic human papillomavirus (HPV).

Castle PE, Hillier SL, Rabe LK, Hildesheim A, Herrero R, Bratti MC, Sherman ME, Burk RD, Rodriguez AC, Alfaro M, Hutchinson ML, Morales J, Schiffman M.

Cancer Epidemiol Biomarkers Prev. 2001 Oct;10(10):1021-7.

33.

HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica.

Hildesheim A, Herrero R, Castle PE, Wacholder S, Bratti MC, Sherman ME, Lorincz AT, Burk RD, Morales J, Rodriguez AC, Helgesen K, Alfaro M, Hutchinson M, Balmaceda I, Greenberg M, Schiffman M.

Br J Cancer. 2001 May 4;84(9):1219-26.

34.

Human papillomavirus type 16 variants and risk of cervical cancer.

Hildesheim A, Schiffman M, Bromley C, Wacholder S, Herrero R, Rodriguez A, Bratti MC, Sherman ME, Scarpidis U, Lin QQ, Terai M, Bromley RL, Buetow K, Apple RJ, Burk RD.

J Natl Cancer Inst. 2001 Feb 21;93(4):315-8. No abstract available.

PMID:
11181779
35.

Cytokine and immunoglobulin concentrations in cervical secretions: reproducibility of the Weck-cel collection instrument and correlates of immune measures.

Hildesheim A, McShane LM, Schiffman M, Bratti MC, Rodriguez AC, Herrero R, Morera LA, Cardenas F, Saxon L, Bowman FP, Crowley-Nowick PA.

J Immunol Methods. 1999 May 27;225(1-2):131-43.

PMID:
10365790
36.

Utility of liquid-based cytology for cervical carcinoma screening: results of a population-based study conducted in a region of Costa Rica with a high incidence of cervical carcinoma.

Hutchinson ML, Zahniser DJ, Sherman ME, Herrero R, Alfaro M, Bratti MC, Hildesheim A, Lorincz AT, Greenberg MD, Morales J, Schiffman M.

Cancer. 1999 Apr 25;87(2):48-55.

PMID:
10227593
37.

Soluble interleukin 2 receptor levels and cervical neoplasia: results from a population-based case-control study in Costa Rica.

Ung A, Kramer TR, Schiffman M, Herrero R, Bratti MC, Burk RD, Swanson CA, Sherman ME, Hutchinson ML, Alfaro M, Morales J, Balmaceda I, Hildesheim A.

Cancer Epidemiol Biomarkers Prev. 1999 Mar;8(3):249-53.

38.

p53 polymorphism and risk of cervical cancer.

Hildesheim A, Schiffman M, Brinton LA, Fraumeni JF Jr, Herrero R, Bratti MC, Schwartz P, Mortel R, Barnes W, Greenberg M, McGowan L, Scott DR, Martin M, Herrera JE, Carrington M.

Nature. 1998 Dec 10;396(6711):531-2. No abstract available.

PMID:
9859989
39.

Collection of cervical secretions does not adversely affect Pap smears taken immediately afterward.

Hildesheim A, Bratti MC, Edwards RP, Schiffman M, Rodriguez AC, Herrero R, Alfaro M, Morera LA, Ermatinger SV, Miller BT, Crowley-Nowick PA.

Clin Diagn Lab Immunol. 1998 Jul;5(4):491-3.

Supplemental Content

Loading ...
Support Center